Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rituxan Comes In Like A Lion With Two New Indications

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA clears Genentech/Biogen Idec’s oncologic Rituxan for rheumatoid arthritis weeks after it was approved for first-line non-Hodgkins lymphoma.

You may also be interested in...



Genentech/Biogen Idec Position Rituxan To Compete Against Anti-TNFs In RA

In Phase III study, treatment with rituximab demonstrated a benefit in biologic-naive patients.

Genentech/Biogen Idec Position Rituxan To Compete Against Anti-TNFs In RA

In Phase III study, treatment with rituximab demonstrated a benefit in biologic-naive patients.

Dr. Reddy's Launches Rituxan Generic

Dr. Reddy's Laboratories launched the first follow-on biologic of the non-Hodgkin's lymphoma treatment rituximab on April 30, the company announced

Related Content

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel